Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1974 1
1977 1
1981 1
1982 1
1984 4
1985 2
1986 4
1987 1
1988 1
1989 2
1990 3
1992 6
1993 2
1994 2
1995 3
1996 4
1997 6
1998 6
1999 4
2000 5
2001 3
2002 2
2003 4
2004 4
2005 3
2006 7
2007 5
2008 7
2009 1
2010 6
2011 3
2012 4
2013 1
2014 5
2015 2
2016 3
2017 4
2018 10
2019 7
2020 2
2021 7
2022 4
2023 6
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

150 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial.
Mori R, Honda S, Gomi F, Tsujikawa A, Koizumi H, Ochi H, Ohsawa S, Okada AA; TENAYA and LUCERNE Investigators. Mori R, et al. Among authors: ohsawa s. Jpn J Ophthalmol. 2023 May;67(3):301-310. doi: 10.1007/s10384-023-00985-w. Epub 2023 Apr 11. Jpn J Ophthalmol. 2023. PMID: 37039948 Free PMC article. Clinical Trial.
Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial.
Shimura M, Kitano S, Ogata N, Mitamura Y, Oh H, Ochi H, Ohsawa S, Hirakata A; YOSEMITE and RHINE Investigators. Shimura M, et al. Among authors: ohsawa s. Jpn J Ophthalmol. 2023 May;67(3):264-279. doi: 10.1007/s10384-023-00979-8. Epub 2023 Mar 10. Jpn J Ophthalmol. 2023. PMID: 36897413 Free PMC article. Clinical Trial.
Efficacy, durability, and safety of faricimab in patients from Asian countries with neovascular age-related macular degeneration: 1-Year subgroup analysis of the TENAYA and LUCERNE trials.
Takahashi K, Cheung CMG, Iida T, Lai TYY, Ohji M, Yanagi Y, Kawano M, Ohsawa S, Suzuki T, Kotecha A, Lin H, Patel V, Swaminathan B, Lee WK; TENAYA, LUCERNE Investigators. Takahashi K, et al. Among authors: ohsawa s. Graefes Arch Clin Exp Ophthalmol. 2023 Nov;261(11):3125-3137. doi: 10.1007/s00417-023-06071-8. Epub 2023 Jun 9. Graefes Arch Clin Exp Ophthalmol. 2023. PMID: 37294433 Free PMC article.
Efficacy, Durability, and Safety of Faricimab in Patients From Asian Countries With Diabetic Macular Edema: 1-Year Subgroup Analysis of the Phase III YOSEMITE and RHINE Trials.
Ishida S, Chen SJ, Murata T, Ogura Y, Ruamviboonsuk P, Sakamoto T, Fujita T, Kawano M, Ohsawa S, Abreu F, Haskova Z, Ives J, Silverman D, Yoon YH; YOSEMITE and RHINE Investigators. Ishida S, et al. Among authors: ohsawa s. Asia Pac J Ophthalmol (Phila). 2023 Sep-Oct 01;12(5):451-459. doi: 10.1097/APO.0000000000000634. Epub 2023 Sep 22. Asia Pac J Ophthalmol (Phila). 2023. PMID: 37851562 Free article. Clinical Trial.
150 results